CICC: Maintains Three S Pharmaceuticals (01530.HK) Outperformed Industry Rating, Raises Target Price to HK$21.10

According to the Wise Finance and Economics app, CICC released a research report stating that it maintains the adjusted net profit of 3SBio (01530.HK) in 2025/2026 at 24.07 billion yuan/26.02 billion yuan (excluding BD down payment income), with the current stock price corresponding to a 17.3/16.0 times adjusted price-earnings ratio for 2025/2026. The rating remains outperforming the industry, considering the increase in the sector's valuation center. The bank raised the target price by 56.3% to 21.10 Hong Kong dollars, corresponding to a 19.0/17.6 times adjusted price-earnings ratio for 2025/2026, implying a 10% upward potential.